JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, W.-S.
Right arrow Articles by Liu, R.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, W.-S.
Right arrow Articles by Liu, R.-S.

Evaluation of Early-Stage Parkinson’s Disease with 99mTc-TRODAT-1 Imaging

Wen-Sheng Huang, Shinn-Zong Lin, Jiann-Chyun Lin, Shiaw-Pyng Wey, Gann Ting and Ren-Shyan Liu

Departments of Nuclear Medicine, Neurological Surgery, and Neurology, National Defense Medical Center, Tri-Service General Hospital, Taipei; Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei; and Institute of Nuclear Energy Research, Lung-Tan, Taiwan, Republic of China



View larger version (62K):

[in a new window]
  		FIGURE 1. 99mTc-TRODAT-1 SPECT in transverse views of healthy volunteer (A) and of patients with HYS stage I (B) and stage II (C) Parkinson’s disease. Asymmetric striatal uptake was observed, with more profound loss contralateral to symptoms or more affected limbs.

 


View larger version (11K):

[in a new window]
  		FIGURE 2. Specific striatal uptake of 99mTc-TRODAT-1 in healthy volunteers and in patients with HYS stage I and stage II Parkinson’s disease.

 


View larger version (11K):

[in a new window]
  		FIGURE 3. Specific putaminal uptake of 99mTc-TRODAT-1 in healthy volunteers and in patients with HYS stage I and stage II Parkinson’s disease.

 


View larger version (13K):

[in a new window]
  		FIGURE 4. Specific putaminal uptake of 99mTc-TRODAT-1 in healthy volunteers and in patients with HYS stage I Parkinson’s disease contralateral and ipsilateral to symptoms.

 


View larger version (12K):

[in a new window]
  		FIGURE 5. Specific putaminal uptake of 99mTc-TRODAT-1 in healthy volunteers and in patients with HYS stage II Parkinson’s disease contralateral and ipsilateral to symptoms.

 


View larger version (15K):

[in a new window]
  		FIGURE 6. Specific posterior putaminal uptake of 99mTc-TRODAT-1 in healthy volunteers and in patients with HYS stage I Parkinson’s disease ipsilateral to symptoms.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.